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Abstract 
Milk is primary food of infants and indispensable part of human diet. There is solid evidence 
of chemicals and drugs presence in milk which raise concerns for toxicological safety of milk. 
Membrane transporters play key role in the transport of chemicals into milk. Transporters 
belong to ABC transporter superfamily e.g. Bcrp, Mdr1 and Mrp1 or SLC transporter family 
e.g. Oatp3 and Octn1. Another considered issue is mastitis which is inflammation of 
mammary gland usually due to bacterial infection. Two major causes of mastitis are 
Staphylococcus aureus and Escherichia coli. 
In this project we studied gene expression of several ABC transporters; Bcrp1, Mdr1, Mrp1 
and SLC transporters Oatp3 and Octn1 in murine mammary epithelial HC11 cells 
differentiated into secreting phenotype. We compared two different cell differentiation 
protocols on HC11 cells and their potential effect on gene expression of membrane 
transporters. We also investigated effects of S. aureus infection and endotoxin treatment 
(LPS) on gene expression of transporters. Expression of transporters was studied by SYBR 
Green RT-PCR. 
The results showed that both cell differentiation protocols caused a downregulation of Bcrp 
and Octn1. In addition, cell differentiation protocol I resulted in a downregulation of Mrp1 
and upregulation of Oatp3. Furthermore, cell differentiation protocol II resulted in a 
downregulation of Mdr1. Octn1 was upregulated in presence of S. aureus and Oatp3 by LPS 
treatment. 
In conclusion, HC11 cells were demonstrated to express all the investigated membrane 
transporters. Some differences between the two evaluated differentiation protocols were 
detected, regarding gene expression of the membrane transporters. However, a common 
observation for both differentiation protocols was a downregulation of Bcrp and Octn1. 
Bacterial infection of HC11 cells resulted in upregulation of Octn1, whereas LPS treatment 
induced upregulation of Oatp3. Further studies are needed to elucidate the physiological role 
of reduced Bcrp and Octn1 in secreting HC11 cells and also to confirm the upregulation of 
Octn1 in S. aureus infected cells and Oatp3 in LPS treated cells 
Key words: milk, HC11 cells, Bcrp, Mdr1, Mrp1, Oatp3, Octn1, mastitis 
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1. Introduction 
1.1.  Mammary gland and milk production 
 
Milk is an important source of nutrients for mammals. It is highly recommended to 
include it in daily diet, and WHO recommends mothers to breast feed their newborns 
for at least 6 months due to mothers’ milk high nutritional quality and reinforcement of 
immunity system of babies. Milk consumption continues to increase globally in 
response to the growing demand every year, e.g. there has been 1.4% increase in its 
production in Sweden from February of 2011 till February of 2012 (1). There has been 
solid evidence of chemicals and drugs presence in milk which raises concerns for 
toxicological safety of milk. Based on extensive studies conducted over transfer of 
drugs into milk, WHO and American Academy of Pediatrics enlist available drugs in 
safe, unsafe or with unclear effects categories for breast feeding women use (2, 3). 
 
1.1.1.  Mammary gland development 
Mammary gland development begins at embryonic stage and continues till parturition. 
At puberty, secretion of estrous hormones commences development of mammary gland 
by triggering epithelial cells proliferation which eventually leads to further development 
of primary ductal structure. In the next step, alveolar buds are formed but they require 
pregnancy for terminal differentiation (4).Secretion of progesterone and prolactin during 
late pregnancy are needed for terminal differentiation of mammary gland and 
appearance of alveoli clusters arranged as secretory lobules, which ultimately produce 
and secret milk (5, 6). β-casein expression and formation of  mammospheres are two 
typical markers of terminal differentiation of mammary cells and their full competence 
for secretion of milk in vivo (7).  
 
1.1.2.  Milk proteins expression and hormonal regulation 
 
Initiation of milk protein expression is similar in humans and mice. Major milk proteins 
are expressed at negligible levels in virgin mice. During gestation, some of the milk 
protein genes start to be expressed while expressions of other genes are mainly 
increased after onset of lactation. At gestation, β-casein appears as the first milk protein, 
followed by whey acidic protein (WAP) and α-lactalbumin at late gestation (6, 8). 
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Hormones play key roles in regulation of cellular differentiation of mammary gland. 
Generally Epidermal Growth Factor (EGF), estrogen (secreted from ovary in estrous 
cycles), and glucocorticoids are required for early development of mammary gland 
(ductal formation) (6, 9). 
Alveolar buds differentiation is prompted by prolactin and progesterone during 
pregnancy. Progesterone arrests β-casein expression during gestation but its level 
decreases at proximity of parturition, while glucocorticoids and prolactin levels 
commence to rise. Prolactin level augmentation leads to terminal differentiation of 
mammary gland, stimulation of β-casein expression (β-casein gene has regulatory 
elements interacting with Stat5, a signaling factor which transfers prolactin response 
(8)) and closure of tight junctions between alveolar cells.  
Glucocorticoids are required for lactation onset, to induce both milk proteins and lipid 
production. Furthermore, tight junction formation is highly dependent on these 
corticosteroids (9, 10).  
 
1.1.3.  Secretion pathways in mammary gland cells 
Two prominent pathways of chemical compounds entrance into mammary lumen are 
transfer by passive diffusion and membrane embedded transporters.   
Passive diffusion connects interstitial space and lumen to each other. This route is 
straight, two-way, cell-independent, and always available even when tight junctions are 
present, but secretion of chemicals is highly dependent of several characteristics (11).  
Molecular size (molecules with 200 D can pass membrane pores), lipophilicity, 
ionization degree, protein-binding affinity and half-life in blood determine their passive 
diffusion into milk (12). 
Membrane transport pathway briefly consists of several types of routes each governed 
by some kinds of proteins. Ion secretion is conducted by channels in apical membrane, 
glucose is transported by especial transporters in apical and basolateral membrane, and 
amino-acids are secreted through sodium dependent and independent transport 
mechanisms. Also xenobiotics can be transported from blood first across the basolateral 
membrane of mammary epithelial cells then across the apical membrane of these cells 
into milk by transporters (11). 
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1.2. Transporters in mammary gland 
 
Two distinctive groups of membrane transporters have been found in charge of drugs 
and xenobiotics transfer across cellular membrane. First group is called ATP-binding 
cassette (ABC), responsible for energy dependent excretion of chemicals. This is a large 
super family of transporters with a similar primary structure and function. All members 
have two distinctive structural domains, transmembrane and nucleotide binding domains 
(NBD). NBDs provide the energy for chemical transport by hydrolyzation of ATP (13, 
14). 
The other prominent group of transporters is Solute Linked Carrier family (SLC) 
consisting of 43 super families of proteins in humans. SLC family members are 
involved in sodium independent transfer of chemicals across cellular membrane (13). In 
contrast to ABC transporters which actively transport chemicals only in one direction, 
SLC members can transfer chemicals in two directions and they do not utilize ATP 
energy for their activity (14). 
 
1.3. Breast Cancer Resistance Protein (Bcrp) 
Breast cancer resistance protein (Bcrp) is an ABC transporter discovered in 1998 by 
Doyle et al., in MC7/AdrVp- a type of multidrug resistant breast cancer cell line (15). It 
is encoded by Abcg2 (Mus musculus) and belongs to ATP- binding cassette, subfamily 
G, member 2. Abcg2 encodes a 657 amino acids polypeptide and 10 splice variants (16). 
Structural studies confirmed that it has half of the ABC transporter structure and it 
should dimerize prior to activation (17). 
BCRP can pump out mitoxantrone, methotrexate, and topotecan and so many other 
chemicals and xenobiotics which makes it very crucial for homeostasis and cellular 
protection against chemicals (18). 
BCRP is widely present in different tissues like apical membrane of placenta 
syncytiotrophoblasts, bile canalicular membrane of liver cells, luminal membrane of 
intestinal epithelial cells, capillary endothelial cells of most tissues apical side of 
alveolar epithelial cells’ membrane in mouse, human and cow (18, 19). 
Immunohistochemical and western blotting experiments showed that it is not expressed 
in virgin mammary tissues but it is extensively expressed through end of pregnancy and 
throughout lactation (18).  
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1.4. Multidrug Resistance Protein 1 (Mdr1) 
Multidrug Resistance Protein 1 (Mdr1) also known as P-gp is a glycoprotein belongs to 
ABC transporters family, subfamily of B (or MDR/TAP) member A1 (Abcb1a, Mus 
musculus ). It was discovered originally in a Chinese hamster ovary by Juliano et al., in 
1976 (21). MDR/TAP family is known to confer cancer resistance, due to export of 
chemotherapeutics out of cells. Mdr1 activity in cells renders multi-drug cancer 
resistance as a result of chemicals removal from cells (20). 
Studies on human ortholog of Mdr1 revealed that is usually transcribed from exon 1 
where its promoter located with no TATA box (22). Its upregulation seems to be 
provoked by NF-κB induction, increase of cytosolic concentration of Ca+2 , and protein 
kinase C and mitogen- activated protein kinases cascades (23) While, its 
downregulation is due to epigenetical changes and methylation (24). 
Generally it transfers neutral or very slightly positively charged lipophilic compounds 
(25) like vinca alkaloids, anthracyclines, and actionomycine D (20). Studies in humans 
and rodents showed that it is expressed in almost all tissue but its extensive expression 
can be detected in tissues with secretory activity e.g. apical membrane of colon, small 
intestine, kidney and adrenal gland. It is also a crucial component of blood-brain barrier. 
In mammary tissue it has been located in apical membrane of epithelial cells and its 
expression seems to be down-regulated in comparison to pregnancy in both humans and 
rats (26, 27). 
 
1.5. Multidrug Resistance Associated Protein 1 (Mrp1) 
Multidrug Resistance associated protein 1 (Mrp1) was first discovered by Cole et al., in 
1992 in a drug resistant lung cancer cell line (28).  It belongs to ABC family of 
membrane transporters, subfamily C (CFTR/MRP), member1 (Abcc1 Mus Musculus). 
It transports a variety of endogenous molecules, such as glutathione- conjugated 
leukotrienes and prostaglandins. It also protects cells against xenobiotics or internal 
toxins (steroids) by pumping them out (20). Mrp1 and Mdr1 display high similarity in 
their activity, it also excretes vinca alkaloids, and actinomycin D like Mdr1. Yet Mrp1 
tends to transfer lipophilic compounds with negative charge (25). It can transfer high 
concentrations of methotrexate, and especially transfer glucoronate, sulfate and 
gluthathione conjugated substrates (20).  
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Its tissue distribution in human and mouse differs. Human MRP1 is abundantly found in 
lung, spleen, bladder, and thyroid but mouse Mrp1 is highly available in ovaries, 
placenta and testes (25). 
In a study by Alcorn et al., Mrp1 expression was studied in rat whole mammary gland 
derived from different days of pregnancy and lactation. Its expression was 
downregulated by onset of lactation and this trend lasted till end of lactation while it 
was upregulated in early involution (26).  Its downregulation is also reported in another 
study of Alcorn et al., in mammary epithelial cells of lactating rat (27). 
 
1.6. Organic Anion Transporting Polypeptide 3 (Oatp3) 
Mouse Organic Anion Transporting Polypeptide 3 (OATP3) was discovered by Abe et 
al., in rat retina’s cDNA library (29). It is encoded by solute carrier organic anion 
transporter, member 1 a 5 (Slco1a5), with seven transcripts variants.  
It has been detected as an influx transporter in transfected COS cells with sodium 
independent activity. It has been also identified in apical side of MDCK cells and small 
intestine jejunal probably for uptake of bile acid (30). 
Xenopus Oocytes containing Oatp3 cRNA were capable of absorbing taurocholate, 
3,5,3’-triido-L-thyronine,and  thyroxine (29). In addition, MDCK cells Transfected by 
rat Oatp3 could absorb glycocholate, glycodeoxycholate, and  taurodeoxycholate (30). 
It has been localized in the brain (chroiod plexus), and epithelial cells of saccule (ear) of 
mouse and lung, retina and small intestine of rat (30).  
Its expression has not been studied in rodents but its human ortholog, OATP- A 
encoded by gene (SLCO1a22) (30) displayed upregulation in lactating mammary 
epithelial cells in comparison to non-lactating epithelial cells (27). 
 
1.7. Organic Cation Transporter, Novel Protein, Type1 (Octn1) 
Organic Cation Transporter, Novel Protein, Type1 (Octn1) encoded by the SLC family 
22, member a4 (Slc22a4, Mus musculus) was first discovered by Tamai et al., (1997) as 
a pH dependent transporter of positively charged organic compounds in humans (31).  
 In addition to its well-studied substrate L-carnitine, it transfers other positively charged 
compounds like, tetra-ethylammonium (TEA), pyrilamine, verapamil (33). 
It has been localized in human fetal and mouse liver, and apical side of epithelial 
membrane of mouse small intestine (33). It is extensively found throughout mammary 
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gland, localized at apical membrane and to less extent in basolateral side of secretory 
alveolar cells in rat and mouse, it has been shown that Octn1 is present in organelle’s 
membrane e.g. mitochondria (32, 34). 
Its expression in mammary gland has been subject of several studies, both Alcorn et al., 
and Lamhonwah et al., reported its upregulation in lactating mammary gland in 
comparison to non-lactating mice and human (27, 34). In another study by Alcorn et al., 
its expression in rat whole mammary gland was studied and it displayed continuous 
upregulation from parturition till day 3, but it decreased slowly through end of lactation 
(26).  
 
1.8.  Mastitis 
Mastitis is the inflammation of mammary gland usually due to bacterial infection within 
it. Mastitis is the major cause of expense among dairy cattle diseases especially due to 
reduction of milk production in infected animals leading to staggering financial losses. 
Staphylococcus aureus is the most common cause of mastitis (35, 36). Pathogens enter 
through teat canal and if they endure animal defense system and proliferate, tissue 
damage occurs including destruction of alveolar cells and disruption of blood-milk 
barrier (35, 37). 
Another common cause of mastitis is Escherichia coli, which may invade animal in 
parturition proximity or early stages of lactation. It also causes severe tissue damage and 
decrease of milk production. E.coli releases endotoxin after its death which is called 
lipopolysaccharide (LPS) (38). 
 
1.9. HC11 cell model 
HC11 cell line is a clonal derivation of COMMA-1D mouse mammary epithelial cell 
line first established by Danielson et al., in 1984. COMMA-1D cell line is isolated from 
murine mammary tissue of BALB / c during mid-pregnancy and quite stable even after 
15 subcultures. It maintains main characterization of murine mammary epithelial cells. 
They can gain and retain lactating phenotype after exposure to certain amount of 
hormones and growth factors (39). 
HC11 cells proliferation requires EGF and insulin, EGF stimulates formation of 
lactogenic hormone responsive cells needed for differentiation (40).  
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Cells differentiation takes place by addition of prolactin, glucocorticoid and insulin, 
while EGF should be removed from medium in prior. Differentiation can be confirmed 
by obtaining spherical phenotype, β-casein expression upregulation and apical to 
basolateral polarization necessary for secretion of milk proteins through lactation. 
About 60 proteins have been identified to be upregulated in differentiated cells e.g., 
cellular components and cytoskeleton proteins undergo upregulation resulting in 
differentiated phenotype in HC11 cell line (41). 
 
2. Aims of Study 
The primary aim of this study was to examine the occurrence of several membrane 
transporters at the gene expression level; Bcrp, Mdr1, Mrp1, Oatp3 and Octn1 in murine 
mammary epithelial HC11 cells differentiated into a secreting phenotype. Other aims 
were to compare the impact on membrane transporter gene expression in secreting 
HC11 cells stimulated to differentiate by two different protocols and the effects by 
S.aureus infection and LPS treatment.  
 
3. Materials and Methods 
3.1. Cell culture 
The HC11 mouse mammary epithelial cells used in the experiments were a kind gift of 
Dr. Bo Lönnerdal, Department of Nutrition, University of California, Davis and used 
with the permission of Dr. Bernd Groner, Institute of Biomedical Research, Frankfurt . 
Passage numbers 26-36 were used in the experiments. The HC11 cells were cultured in 
sterile Roswell Park Memorial Institute (RPMI) 1640 basal medium , pH 7.4, (2mM L- 
Glutamine ,25 mM HEPES) (GIBCO, Invitrogen, Carlsbad, CA, USA), Gentamycin 50 
mg/L (Gibco, Invitrogen, Carlsbad, CA, USA) , Sodium Bicarbonate 7.5% (w/v), 
human insulin solution 5mg/L ( Sigma- Aldrich, St. Louis, USA), Epidermal growth 
factor (EGF) 10 µg/L, and 10% (v/v) heat –inactivated -Foetal  bovine serum (FBS) 
(Gibco, Invitrogen, Carlsbad, CA, USA). The cells were cultured at 37˚C and 5% CO2 
in a Sanyo incubator (MCO-18AIC (UV), Japan). Medium was changed every second 
day. 
To passage cells, when they reached 80% confluence , the growth medium was removed 
and cells were washed by DMEM (15ml/75 cm
2 
) and  3 ml of cell dissociation buffer 
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(enzyme-free PBS-based) (Gibco , Invitrogen , Paisley , UK)  was added to the cells. 
Cells were then incubated for 20 minutes in incubator at 37 ˚C . Thereafter, 12 mL of 
growth medium added to the cell culture flask and cell suspension prepared by pipetting 
up/ down several times. Centrifugation of the cell suspension was then performed for 5 
minutes at 50x g . Prior to centrifugation a 160 µl aliquot was taken from the cell 
suspension which was stained by addition of Trypan blue 0.4% (Gibco, Invitrogen). 
Counting of cells was then carried out by the use of a Bürchner chamber. After this, the 
cell pellet was resuspended in growth medium. For seeding cells in 6 well- plate 10 
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cells were added to each well and for T75 flask 1.5x10 
6 
cells were added. 
 
3.1.1.  Cell differentiation protocol I 
 
Cells were cultured in growth medium 4 days post 100 % confluency. The cells were 
then washed with DMEM (15ml/75 cm
2 
or 2 ml/ per well for 6 well-plate) in order to 
remove medium residues and dead cells. DMEM was removed and replaced with 
differentiating medium. Differentiating medium had a similar composition as the 
growth medium with the difference that  FBS and EGF were replaced by prolactin 1 
mg/L  (Sigma- Aldrich, St. Louis, USA) and cortisone 1 µM (Sigma- Aldrich, St. Louis, 
USA). Stimulation of the HC11 cells to differentiate into a secreting phenotype was 
accomplished by incubating the HC11 in differentiating medium for 3 days.  
 
3.1.2.  Cell differentiation protocol II 
When cells reached 100% confluency, they were cultured in growth medium for an 
additional 6 days. On day seventh of postconfluence growth medium was removed and 
cells were washed by DMEM (15ml/75 cm
2 
or 2 ml/ per well for 6 well-plate) to 
thoroughly remove all EGF and then cultured in EGF-free growth medium for one day. 
Cells were washed with DMEM as described above and then incubated with 
differentiating medium for at least 3 days. Lactogenic phenotype- mammospheres were 
observed and checked by phase-contrast microscope Olympus as an indication of true 
cell differentiation. 
 
 
3.1.3.  Induction of inflammation by Staphylococcus aureus 
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Cells were differentiated according to cell differentiation protocol II in two six well 
plates. One day prior to the infection experiments cells were incubated with antibiotic-
free differentiating medium. On each plate 1x 10ˆ 6 colony forming unit (CFU)/ml was 
added to three of the wells while only medium was added to other three wells (used as 
negative controls). The total volume added to each well was 3 ml. Cells were incubated 
at 37 ˚C for two hours, medium was then removed and cells were washed by HBSS 
twice. After washes, RPMI medium containing 100 µg/ml gentamycin was added and 
plates incubated for an additional five hours. After this, cells were washed with HBSS 
and either lysed with RA1 buffer (Macherey- Nagel) for RNA isolation or Milli Q water 
for determination of intracellular bacteria number. Samples taken from water lysates 
were serial diluted and   spread on Beef blood agar. Colonies were counted following 
one day of incubation at 37˚C. RA1 lysates were stored at -70 ˚C freezer prior to 
isolation of RNA and gene expression analyze.  
 
3.1.4.  Induction of inflammation by LPS on HC11 cells 
To induce experimental inflammation on HC11 cells, Two T75 Flasks of differentiated 
cells were used. Cells in one flask were treated with differentiating medium containing 
LPS 10 µg/mL (Sigma-Aldrich, St. Louis, USA) for 48 hours. Control cells were treated 
with differentiating medium without LPS. These two flasks were incubated at 37 ˚C and 
5% CO2. 
 
3.1.5. Cell toxicity test for LPS-treated cells 
 
Medium Samples from both LPS and control cells were taken and stored at -20 ˚C 
freezer. NADH stock solution (175 µl at concentration of 6.6 mM) was added to 4.65 
ml of Tris HCl buffer (at concentration of 0.2mM and pH 7.3) and mixed thoroughly. 
195 µl of this solution was added to 10 µl of medium sample (each samples were in 
duplicate). The mixture (loaded in 96 well-plate) were incubated at room temperature 
for 15 minutes and then at 25 ˚C in a microplate reader Victor2 1420 multilabel counter 
(Perkin Elmer, Wellesley, USA). 15 µl of sodium pyruvate (30mM) was added to each 
well and absorbance values at 340nm recorded 6 times/well. Lactate dehydrogenase 
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activity in the collected medium samples was calculated by the formula presented 
below: 
LDH(U/mL)= ΔA per minute/ (0.001 x 0.1x 0.8) 
 
3.2. RNA isolation 
Total RNA was extracted from cells or tissue samples by the use of Nucleospin
®
 RNA 
II kit (Macherey-Nagel, Düren, Germany). Mammary tissues were obtained from 
previous experiments with lactating mice approved by the Local Ethics Committee of 
Animal Research (permit no. C159/2).The whole procedure was performed according to 
manufacturer’s manual; every 30 mg of tissue sample or 5x106 of cultured cells was 
lysed by RA1 buffer (containing 1% β-mercaptoethanol) and RNA precipitated by 
addition of 70% ethanol. The lysate added to a filtered column and washed by 
membrane desalting buffer. DNA was digested by addition of DNase I reaction mixture 
(containing 10% reconstituted rDNase) and incubated for 15 minutes at room 
temperature. The bound RNA washed by RA2 and RA3 buffer and finally eluted at 60 
or 50 µl of RNase-free H2O. 
 
3.3. Total RNA quantification and RNA gel electrophoresis 
Quantification of total RNA isolated from cells or tissue was carried out by the use of 
Ribo-Green 
® 
RNA Quantification Kit (Molecular Probes, Invitrogen, Eugene, USA). 
RNA concentration was determined by following the instruction of manufacturer’s 
manual. Ribosomal RNA was used as a RNA standard at concentrations of 0.02, 0.1, 
0.5 and 1 µg/ mL loaded in duplicates and diluted samples were loaded in triplicates in 
96 well plates (dilution rate was 200 to1600 times, depending on the concentarion of the 
isolated RNA). Fluorescence was measured in Victor
2 
1420 multilabel counter (Perkin 
Elmer, Wellesley, USA). The equation obtained by the RNA standards was used to 
calculate concentration of samples. 
The integrity of RNA after isolation was checked by running at least 300 ng of RNA 
sample on 1% agarose (Sigma-Aldrich, St. Louis, USA) at 60 V for 90 minutes. Two 
bands of ribosomal RNA were observed as in indication of intact RNA (28s and 18s 
rRNA) (Figure1). 
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Figure 1. RNA gel electrophoresis of isolated RNA from HC11 cells differentiated according to first cell 
differentiation protocol; two distinct rRNA bands in gel are an indication of intact RNA. Lane 1-6 RNA from 
undifferentiated cells & 6-12 differentiated cells. 
Concentration of RNA standard which were used to draw the standard curve is shown in 
table 1 at bellow.  
 
 Table 1-RNA standard concentration and their fluorescence after measurement in Victor, values from duplicates were used 
to calculate average and then background was subtracted from them obtaining true fluoresce. 
Standard RNA 
concentration (ng/mL) 
Duplicate 1 Duplicate 2 average True fluorescence 
0 2473 2126 2299,5 0 
20 8531 8865 8698 6398,5 
100 38630 40312 39471 37171,5 
500 179692 183349 181520,5 179221 
1000 316344 329991 323167,5 320868 
 
Values from table 1 were used to draw the following graph. One equation was obtained 
from standard curve (Figure 2) which was used for calculation of RNA concentrations 
in unknown samples. 
 
Figure 2. Standard curve of Ribo- Green assay; equation of regression line was used for 
fluorescence values of known samples to calculate RNA concentrations. 
Concentration of RNA in unknown samples were calculated according to the equation 
shown in figure 2 , an example of calculated concentrations for the RNA isolated from 
y = 323.82x + 3813.2 
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HC11 cells treated with cell differentiation I passage number 31 is shown below in table 
2.  
 
Table 2. RNA samples measured by Ribo-Green assay, each sample was loaded as triplicate, mean 
values were calculated and corrected for background and concentration obtained according to 
equation. 
Samples name Mean Fluorescence 
value of samples 
Correction for 
background 
RNA 
concentration(ng/mL) 
1 29868.3 27568.8 117.376 
2 123517 121217.5 580.096 
3 85164 82864.5 390.592 
4 79701 77401.5 363.600 
5 42378.3 40078.8 179.072 
6 54117 51817.5 237.184 
7 28043.6 25744.1 108.3609 
8 22933 20633.5 83.104 
9 23894.3 21594.8 87.856 
10 21119.6 18820.1 74.144 
11 33794 31494.5 136.768 
12 26997.6 24698.1 103.184 
 
 
3.4. Primer Design and DNA gel electrophoresis 
 
Primers were designed to detect expression of two genes in samples; Slc22a4 (solute 
carrier family 22, member4 (Gene ID: 30805)) encoding Organic cation transporter 
protein, novel, type1 (OCTN1) and Slco1a5 (solute carrier organic anion transporter 
family, member 1a5 (Gene ID: 108096)) Organic anion transporting polypeptide 
3(OATP3). To design primers cDNA of these genes were obtained from NCBI database 
(www.ncbi.nih.gov) and intron-spanning primers picked in Primer 3 software to have 
PCR product of 150-200 base pairs. Primers were generated by Cybergene Company 
(Stockholm, Sweden). Sequences of primers are listed below in table 3. 
Table 3- OCTN1 and OATP3 primer sequence 
Protein Primer Sequnce 
OCTN1 5’-CCTGTTCTGTGTTCCCCTGT-3’ (Forward) 
5’- GGTTATGGTGGCAATGTTCC-3’ (Reverse) 
OATP3 5’-GCACAGAGAAAAAGCCAAGG-3’ (Forward) 
5’- CTCCAGGTATTTGGGCAAGA-3’ (Reverse) 
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PCR product of these primers were run on 1% agarose at 60 V for 90 minutes, to check 
if primers attach specifically and their products have the right size. 
 
3.5. Reverse Transcription real-time PCR: 
To study gene expression in HC11 cell line or tissue samples, QuantiTect 
®
SYBR 
®
 
Green RT-PCR kit (Qiagen, Hilden, Germany) was used. Each sample was run in 
duplicate containing 100 ng of template RNA sample and 0.4 µM of primer in 25 µ l of 
reaction mix. PCR program was; 50 ˚C – 30 minutes, 95˚C – 15 minutes, 40 cycles 
(each cycle 94˚C- 1 minute, 55˚C- 1 miunte, 68˚C- 45 seconds), 68˚C- 7 minutes. Melt 
curve analysis from 50˚C to 99˚C was performed in direction to the RT-PCR. Both RT-
PCR and melt curve analyses were performed by using a Rotor Gene (RG3000, Corbett 
Life Science, Sydney, Australia). 
One example of melt curve generated by Rotor gene is shown below (Figure3). Melt 
curves were used to check accuracy of PCR runs in by observing the melt peak at the 
same temperature. 
 
 
Figure 3: Melt curve of β-casein expression in HC11 cells differentiated according to cell differentiation protocol II .100ng of 
RNA template was used (passage number 33), differentiated and undifferentiated cells RNA were loaded in duplicates 
(N=3). 
 
3.6. Statistical analysis: 
To determine if there has been any statistically significant difference between treated 
and un- treated samples all data obtained from qRT-PCR has been analyzed by MiniTab 
16 Statistical software, and reported as Mean ± standard deviation. Two set of data 
analyzed by ANOVA test (one-way unstacked); difference between sets of data is 
significant when p value is ≤ 0.05. 
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4. Results 
4.1. Gene expression of transporter in mouse mammary tissue 
As a quality control, the PCR gene expression of transporters was investigated in mouse 
mammary tissue isolated in different days during lactation; day 2 (early lactation), day 
7(peak lactation) and day 20 (late lactation -involution). For this experiment mouse 
mammary tissue isolated from one individual was used in duplicates to obtain 
expression pattern of transporters during lactation. Day 2 was chosen as a standard for 
basal expression and all expression values were normalized to day 2. No statistical 
analysis was performed for these data. 
 
β- casein gene expression was upregulated through early lactation to peak lactation, but 
downregulated at  the end of lactation (Figure 3). Bcrp gene expression was upregulated 
from early to peak lactation but it was slightly decreased through end of lactation 
(Figure 4), while Mdr1 gene expression was dramatically downregulated from early to 
peak lactation but it was slightly increased through end of lactation (Figure 5). Mrp1 
gene expression remained at the same level as lactation day 2 through lactation with a 
weak tendency for upregulation at day 7 (Figure 6). Oatp3 gene expression was 
dramatically downregulated from early to peak lactation but it began to increase through 
end of lactation (Figure7). Octn1 gene expression did not change from early to peak 
lactation but it decreased through end of lactation (Figure 8). 
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Figure 3. β-casein expression in mammary tissue of lactating mouse. Mean value of each lactation 
day was normalized to day 2. 
 
 
 
Figure 4.  Bcrp expression in mammary tissue of lactating mouse. Mean value of each lactation day 
was normalized to day 2.  
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Figure 5. Mdr1 expression in mammary tissue of lactating mouse. Mean value of each lactation day 
was normalized to day 2.  
 
 
 
 
Figure 6. Mrp1 expression in mammary tissue of lactating mouse. Mean value of each lactation day 
was normalized to day 2. 
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Figure7. Oatp3 expression in mammary tissue of lactating mouse. Mean value of each lactation day 
was normalized to day 2. 
 
 
 
Figure 8. Octn1 expression in mammary tissue of lactating mouse. Mean value of each lactation day 
was normalized to day 2.  
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4.2. Gene expression of transporters in cell differentiation protocol I and 
II  
HC11 cells passage number 31 and 33 were differentiated to obtain secreting phenotype 
by protocol I and II, respectively and protocols were compared in order to find out 
which protocol induces differentiation better. These two protocols are different in 
respect of differentiation time. HC11 cells were differentiated during 7 days post-
confluency in protocol II, compared to because 3 days in protocol I.  
β- casein expression was analyzed in cells as a marker of differentiation of HC11 cells 
into a  secreting  phenotype.  Both protocols induce β- casein upregulation but protocol 
I provoked upregulation about 30 folds higher than protocol II (Figure 9). Bcrp gene 
expression was studied in HC11 cells differentiated by both protocols I and II. In HC11 
cells differentiated by either of protocols, Bcrp expression was downregulated (Figure 
10). Mdr1 expression was significantly downregulated in HC11 cells when they were 
differentiated by protocol II, but no difference in expression was observed for HC11 
cells differentiated according to protocol I (Figure 11). Mrp1 expression was 
significantly downregulated in HC11 cells when they were differentiated by protocol I, 
but its expression did not change after differentiation by protocol II (Figure 12). Oatp3 
expression was significantly upregulated in HC11 cells when they were differentiated 
by protocol I (about two fold increase in expression), but its expression in HC11 cell 
differentiated according to protocol II showed a tendency to be downregulated although 
no statistically significant difference in expression was obtained from F test analysis 
(ANOVA, one-way unstacked) (Figure 13). Octn1 expression was significantly 
downregulated in HC11 cells differentiated by either of protocols which is contrary to in 
vivo studies, but downregulation in cells differentiated according to protocol I was more 
(less than half of the expression of Octn1 in control cells) than protocol II (Figure 14). 
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Figure 9. Comparison of β-casein expression in HC11 cells. Mean values and standard deviations of 
control and differentiated cells for both protocol I and II are shown on graph after normalization 
(N=6, N=3 for protocol I and II respectively). (* P value ≤0,05) 
 
 
 
Figure 10. Comparison of Bcrp expression in HC11 cells. Mean values and standard deviations of 
control and differentiated cells for both protocol I and II are shown on graph after normalization 
(N=6, N=3 for protocol I and II respectively). (* P value ≤0,05) 
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Figure11. Comparison of Mdr1 expression in HC11 cells. . Mean values and standard deviations of 
control and differentiated cells for both protocol I and II are shown on graph after normalization 
(N=3, N=3 for protocol I and II respectively). (* P value ≤0, 05) 
 
 
 
Figure 12. Comparison of Mrp 1 expression in HC11. Mean values and standard deviations of 
control and differentiated cells for both protocol I and II are shown on graph after normalization 
(N=6, N=3 for protocol I and II respectively). (* P value ≤0, 05)  
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Figure 13. Comparison of Oatp3 expression in HC11 cells. Mean values and standard deviations of 
control and differentiated cells for both protocol I and II are shown on graph after normalization 
(N=3, N=3 for protocol I and II respectively). (* P value ≤0, 05) 
 
 
Figure 14. Comparison of Octn1 expression in HC11 cells. Mean values and standard deviations of 
control and differentiated cells for both protocol I and II are shown on graph after normalization 
(N=3, N=3 for protocol I and II respectively). (* P value ≤0, 05) 
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4.3. Gene expression of transporters during subclinical mastitis and LPS 
treatment 
To investigate the impact of subclinical mastitis on transporters gene expressions, HC11 
cells (passage number 31) were infected by Staphylococcus aureus and RNA was 
isolated. HC11 cells (passage number 36) were treated by LPS to simulate E.coli 
mastitis for investigation of any potential impacts on transporters gene expression.  
To check if LPS treatment had any lethal effect on cells by damaging cell membrane 
structure, cell toxicity test was performed.  
LDH concentration was measured and the obtained results are displayed in Figure15. 
LDH concentration was not increased in HC11 cells treated by LPS.  
 
 
Figure 15. Results of cell toxicity test on HC11 cells, passage number36. LDH concentration was 
measured as an indicator of cell membrane damage in medium from LPS-treated cells and from 
controls = Non-LPS-treated (NLPS). Both media had lower LDH concentration than low- LDH 
control. 
 
Cell toxicity test had been performed on HC11 cells infected by S. aureus previously in 
the lab, and no cell membrane damage was detected in HC11 cells on that assay but the 
results are not included.  
β-casein gene expression was studied in differentiated HC11 cells in both S.aureus 
infection and LPS treatment. At infection state, it showed a tendency for upregulation 
without any statistically significant difference, while LPS treatment seemed to have no 
especial effects on its expression (Figure16). Bcrp and Mdr1 expressions in both 
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infected HC11 cell and LPS –treated did not change recognizably (Figure 17 & 18). 
Mrp1 expression also did not change by either S.aureus or LPS treatment (Figure 19). 
Oatp3 was upregulated significantly after LPS treatment comparing to control cells but 
no change was detected in S.aureus infected cells (Figure20). Octn1 was upregulated in 
presence of S. aurues but no clear tendency was observed in LPS treatment (Figure21). 
 
 
Figure 16. β-casein expression in HC11 cells in presence of S. aureus & LPS. Mean values and 
standard deviations of control and treated cells are shown on graph after normalization (N=3, two 
controls were included in S.aureus HC11 cells). 
 
Figure 17. Bcrp expression in HC11 cells in presence of S. aureus & LPS. Mean values and standard 
deviations of control and treated cells are shown on graph after normalization (N=3, two controls 
were included in S.aureus HC11 cells). 
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Figure 18. Mdr1 expression in HC11 cells in presence of S. aureus vs LPS. Mean values and 
standard deviations of control and treated cells are shown on graph after normalization (N=3, two 
controls were included in S.aureus HC11 cells).  
 
 
Figure 19. Mrp1 expression in HC11 cells in presence of S. aureus vs LPS. Mean values and 
standard deviations of control and treated cells are shown on graph after normalization (N=3, two 
controls were included in S.aureus HC11 cells).  
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Figure 20. Oatp3 expression in HC11 cells in presence of S. aureus & LPS Mean values and 
standard deviations of control and treated cells are shown on graph after normalization (N=3, two 
controls were included in S.aureus HC11 cells) . It was upregulatedin presence of LPS but it showed 
a tendency for downregulation in presence of S. aureus (* P value ≤0, 05). 
 
Figure 21. Octn1 expression in HC11 cells in presence of S. aureus & LPS Mean values and 
standard deviations of control and treated cells are shown on graph after normalization (N=3, two 
controls were included in S.aureus HC11 cells). It was evidently upregulated in presence of S. 
aureus (* P value ≤0, 05). 
 
5. Discussion 
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different protocols. Also gene expressions of them were studied when differentiated cells 
were infected by S. aureus or exposed to LPS to simulate subclinical mastitis. 
As a quality control of the PCR technique, we studied gene expression of target 
transporters in murine mammary tissues isolated from lactating mouse and expression 
levels of transporters were studied in tissues from lactation day 2, 7 and 20. Some genes 
showed upregulation through lactation, while some were downregulated or their 
expression did not change during lactation. β-casein, and Bcrp were highly upregulated, 
while Mdr1 and Oatp3 were strongly downregulated during lactation, but Octn1 was 
downregulated at the end of lactation. Mrp1 did not display any change in expression 
level. 
All data of in vivo experiment, was in complete accordance with previous studies 
performed by other research groups. Bcrp1 gene expression was strongly upregulated in 
mouse mammary gland. Immunohistochemical and western blot studies of Bcrp1 by 
Jonker et al. showed the same result (18). Mdr1 gene expression was found downregulated 
in our study, which is in line with reports of its downregulation in mammary gland of 
humans and rats through lactation (26, 27). Mrp1 gene expression did not show any 
change from lactation day2 till day 20, while in the study by Alcorn et al. (26) on lactating 
rat mammary gland its expression was downregulated at the beginning of lactation and 
remained at low levels through it. Since we did not include pregnant mouse mammary 
tissue at late gestation, no comparison between its expression levels in lactation with 
pregnancy period could be performed to confirm a true downregulation.  
Oatp3 gene expression, to my knowledge, was studied for the first time in murine 
lactating mammary gland and its expression was shown to be decreased through lactation 
while OATP-A (its human ortholog) was reported to be upregulated in epithelial cells of 
human mammary tissue during lactation (27). Octn1 expression in a study by Alcorn et al. 
was reported to be upregulated from parturition till day 3 in rat mammary gland but it 
decreased through end of lactation (26), while in our study the Octn1 expression was 
highest in day 7. The difference between results of this study and Alcorn’s can be result of 
intense upregulation of Octn1 between day 2 and day 3 of lactation which was skipped in 
this study.  
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5.1.  Cell differentiation protocol effect on gene expression of transporters 
In this study, we used two different cell differentiation protocols to induce secreting 
phenotype in HC11 cells, to optimize an in vitro model for membrane transporters 
during lactation. In both protocols prolactin, glucocorticoids and insulin were added to 
cells to induce terminal differentiation but protocols was different in respect of timing. 
In protocol I cells were differentiated 4 days post-confluency, while in protocol II cells 
were differentiated after 7 days post-confluency. 
We investigated gene expression of transporters in differentiated HC11 cells to compare 
their potential similarity to in vivo conditions. β-casein upregulation is a marker for 
secreting phenotype in mammary cell lines. Differentiation of cells according to 
protocol I resulted in a stronger expression of β-casein than protocol II (30 folds higher 
expression was detected in HC11 cells differentiated by protocol I). Detection of such 
considerable expression difference between the two protocols can be result of allowing 
cells to be confluent for 3 days more in protocol II than protocol I. It should be 
mentioned that, HC11 cells were primarily isolated from mouse at mid-pregnancy, 
when β-casein expression is already elevated. Since, HC11 cells according to protocol II 
were allowed to stay in growth medium for longer time prior to differentiation 
comparing to protocol I, β-casein expression might increase further in control cells 
leading to detect higher expression level of β-casein in protocol II control cells. 
Consequently, the relative expression fold difference between control and differentiated 
cells reduces which leads to detection of less gene expression increase in return. 
Some transporters expression was in accordance with previous studies, while others do 
not show the expected expression pattern.  
Bcrp1, Mdr1and Octn1 did not show the expected expression pattern in differentiated 
HC11 cells. Bcrp1 expression decreased in HC11 cells, which was in contrast to in vivo 
studies that reported its upregulation (18). Mdr1 was supposed to be downregulated in 
mammary epithelial cells while its expression did not change after differentiation (26). 
Alcorn et al. reported its notable downregulation in mammary epithelial cells isolated 
from human tissue (27). Mrp1 expression was downregulated in our study, as 
previously reported in studies on rat mammary tissue and human mammary epithelial 
cells (26, 27).  
Octn1 was expected to be upregulated in HC11 cell based on previous findings (26, 27, 
34), while it was obviously downregulated in our experiments. Alcron et al. reported its 
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upregulation in human mammary epithelial cells (27). Oatp3 has not been studied in 
mouse, yet its human ortholog (OATP-A) was reported to be upregulated in Alcorn et al. 
study in human mammary epithelial cells during lactation (27). In our study, its 
expression in murine tissue was downregulated at peak lactation (day 7). Since, 
differentiated HC11 cells are supposed to display peak lactation phenotype, it  might be 
concluded that downregulation of Oatp3 in HC11 cells was in complete accordance to 
in vivo situation when it was found downregulated at day 7.  
Membrane transporters genes in differentiated HC11 cells did not follow the in vivo 
studies pattern for Bcrp1expression, which was reported to be markedly upregulated, in 
fact, its expression in differentiated HC11 cells by both protocols was downregulated in 
our study. Mrp1 expression did not change in differentiated HC11 cells by protocol II. 
Its expression in both rat mammary tissue and human mammary epithelial cells was 
downregulated during lactation (26, 27). 
Mdr1 was downregulated like in vivo studies on rat mammary gland (26). Octn1 
displayed similar expression patterns in HC11 cells differentiated according to either 
protocol I or II.  Oatp3 showed a tendency for downregulation without any statistically 
significant difference with control cells due to large standard deviation. 
As a result of obtaining unexpected expression level of transporters in differentiated 
HC11 cells by either protocol I or II, it is difficult to choose either of protocols as an 
optimal method for differentiation. Several reasons can be suggested for detection of 
different gene expression in differentiated HC11 cells. First of all, gene expressions of 
transporters have been usually studied in vivo, which includes RNA sample of a 
conglomerate of different cell types within tissue. Each cell type might have distinctive 
expression for membrane transporters, while RNA contents of all cell types mix during 
RNA isolation procedure and target mRNA may dilute or concentrate in the final 
aliquot. Furthermore, post-transcriptional regulation has been proposed to be a very 
prominent process in HC11 cells especially during differentiation that may result in 
difference between mRNA and protein level at time of detection (41). 
 
5.2. S.aureus infection and endotoxins effect on gene expression of 
transporters 
Very few studies have been conducted on transporter gene expression during mastitis 
and information on gene expression of transporters is not available extensively. We 
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tried to simulate infection condition in an in vitro cell model (HC11 cells) and 
investigate potential impact of S. auerus or E.coli infection on membrane transporters 
expression. We used differentiated HC11 cells by protocol II and treated them with S. 
aureus and LPS. 
Most of transporters showed no significant difference in expression in either of 
conditions. This can be due either to a too low dose of LPS or that genes are not 
affected by LPS. In infection experiment by S.aureus, the only affected transporter was 
Octn1 which was upregulated. β-casein expression displayed a tendency for 
upregulation in presence of S.aureus.  
In LPS treated HC11 cells just Oatp3 showed alteration in expression pattern and it was 
upregulated in presence of endotoxins. Also Mrp1 displayed a tendency for upregulation 
but standard deviation of data was too large to be considered statistically significant. 
Mrp1 mRNA and protein concentrations were studied by Vos et al. (42) and it showed 
upregulation at both levels after 6 hours exposure to LPS. β-casein secretion in mastitic 
dairy cows (E.coli infection) was shown to be increased by Boehmer et al. (43). But this 
had been reported by measuring the protein and cannot be accepted as a clear indication 
of gene upregulation, since possible post-translational regulation mechanisms may 
interfere. We could not detect its upregulation in LPS experiment. Mdr1 expression had 
been checked in epithelial cells of small intestine and liver cells during mastitis. In both 
tissues its expression was downregulated and its efflux activity impaired (44, 45) but we 
did not detect any change of its expression. Octn1 as an L-carnitine transporter was 
studied in rat mammary gland by Alcorn et al., during induced LPS mastitis (46) and it 
was observed that Octn1 was upregulated at lactation day 4 and day 11. 
 
6. Conclusion 
HC11 cells were demonstrated to express all the investigated membrane transporters. 
Some differences between the two evaluated differentiation protocols were detected, 
regarding gene expression of the membrane transporters. However, a common observation 
for both differentiation protocols was a downregulation of Bcrp and Octn1. Bacterial 
infection of HC11 cells resulted in upregulation of Octn1, whereas LPS treatment induced 
upregulation of Oatp3. Further studies are needed to elucidate the physiological role of 
reduced Bcrp and Octn1 in secreting HC11 cells and also to confirm the upregulation of 
Oatp3 in LPS treated cells and Octn1 in S. aureus infected cells. 
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